Adicet Bio, Inc.
Business
Adicet Bio, Inc. is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies to treat autoimmune diseases and cancer. It develops “off-the-shelf” engineered gamma delta CAR T cell product candidates, including lead programs ADI-001 (anti‑CD20) for B‑cell mediated autoimmune diseases and ADI-270 (anti‑CD70) for renal cell carcinoma, plus discovery and preclinical programs. Its activities span clinical development, cGMP manufacturing and process scale-up, intellectual property and strategic collaborations. It targets patients in the United States, Europe, China, Japan and other global markets through clinical trials, CDMO partnerships and cryopreserved off‑the‑shelf distribution.
Summary from filing dated 2025-03-06
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-116.80M |
| Total assets | — |
| Total liabilities | — |
| Stockholders' equity | — |
| Operating cash flow | $-95.25M |